羧甲司坦治疗稳定期慢阻肺患者临床观察

目的：观察羧甲司坦治疗稳定期慢性阻塞性肺疾病（COPD）患者的临床疗效.方法：88例稳定期COPD患者随机分为观察组和对照组各44例,对照组予常规治疗,治疗组在对照组基础上加用羧甲司坦片0.5 g,po,tid.治疗6个月后测定两组肺功能、Borg呼吸困难评分、6 min步行距离（6MWT）,统计沙丁胺醇使用次数及急性加重发作次数,进行圣乔治呼吸问题调查问卷（SGRQ）;记录不良反应.结果：治疗后,治疗组6MWT明显延长,Borg评分显著下降;使用沙丁胺醇（17.1±5.8）次,急性发作（0.4±0.2）次;生活质量评分显著提高,各项指标均明显优于对照组（P＜0.05或0.01）.两组治疗过程中均无明显不适出现.结论：长期服用羧甲司坦可明显提高稳定期COPD患者的运动能力,改善呼吸困难及生活质量.

Clinical Effect Observation of Carbocisteine in the Treatment of Stable Phase COPD

Objective： To observe the clinical effects of carbocisteine in the treatment of chronic obstructive pulmonary disease （COPD） in stable phase. Methods： Totally 88 patients were randomly divided into the study group and the control group. The control group was treated with the conventional therapy, while the study group received carbocisteine additionally. The treatment course was 6 months. Pulmonary function, Borg dyspnea score, 6-minute walking distance （6MWT）, use times of salbutamol, the frequency of a- cute exacerbation, St george＇s respiratory questionnaire（SGRQ） and the adverse reactions were recorded. Results： After the treatment in the study group, the 6MWT increased, Borg dyspnea score decreased, the use times of salbutamol was （ 17.1 ± 5.8）, the frequency of acute exacerbation was （0.4 ± 0.2 ）, the score of SGRQ increased, and there were significant differences between the two groups （ P 〈0.05 or 0.01 ）. No evident discomfort was shown during the treatment. Conclusion： For the patients of stable phase COPD, the sport ability, dvspnea and quality of life can be improved by the lone-term administration of carbocisteine.